Ibs joined Abingworth as an Operating Executive in May 2024 and will work with new and existing portfolio companies to support their clinical and operational capabilities, with a particular focus on the Republic of Ireland.
Ibs began his career in life sciences as an Investment Banker at Nomura and then lead life sciences equity research at Investec. In 2011 he co-found DrugDev.com, a clinical trial automation software company, which was acquired by IQVIA. Ibs remained at IQVIA as global head of its clinical technology business ahead of co-founding AMO-Pharma, a biotechnology company focusing on orphan CNS diseases where he was CEO until April 2024. He also co-founded Induction Healthcare and spent time setting up venture capital at Shire and as an Entrepreneur-in-Residence for Oxford Science Enterprises. Ibs brings to Abingworth extensive knowledge of CROs and the clinical trial software space as well as biotech operations experience more generally.
Ibs obtained a degree in Medicine from Oxford University.
